Abstract Symposia Tuesday

Tuesday, July 2, 13.00-14.15

AS-13: Role of FXII activation in mechanism of thrombosis

  • Factor XII: what’s new?
    Nicola Mutch

AS-14:  Methods and relevance of microparticle detection

  • Microparticle detection: why and how?
    Paul Harrison

AS-15: New approaches to antiplatelet therapy

  • Clinical use of purinergic receptor blockers
    Richard Becker

AS-16: Functional characterisation of hereditary platelet disorders

  • Genetics, platelet dysfunction and bleeding
    Kathleen Freson

AS-17: Challenges in therapeutic  management of VTE

  • Aspirin for the prevention and treatment of venous thromboembolism
    Cecilia Becattini

AS-18: Prevention of recurrent VTE

  • Management and prognosis after a first venous thrombosis
    Sabine Eichinger

AS-19: Vascular disorders

  • Chronic thromboembolic pulmonary hypertension – a model disease for vascular occlusion
    Irene Lang

AS-20: New developments in treatment of VTE

  • New anticoagulants for venous thrombosis:  opportunities and challenges
    Jeffrey Weitz

AS-21: The interplay between coaulation and inflammation

  • Tissue factor signaling and inflammation
    Wolfram Ruf

AS-22: Inhibitors in Haemophilia A

  • Haemophilia inhibitors
    Anske van der Bom

AS-23: What’s new in fibrinolysis?

  • Plasminogen activator inhibitor-1: what’s new?
    Douglas Vaughan

AS-24: Pleiotropic effects of fibrinogen

  • A possible role for Fibrin in Alzheimer’s disease
    Sidney Strickland